Merck & Co. said Thursday it will cut U.S. list prices for several of its drugs including the hepatitis C treatment Zepatier, and the company pledged to limit future net price increases.
It was the latest nod by a drugmaker to public pressure over drug costs. Novartis AG and Pfizer Inc. said in recent days they wouldn’t raise U.S. drug prices further this year, in Pfizer’s case after President Donald Trumpblasted on Twitter the company’s plans for a new round of increases.
...